Brazil’s National Health Surveillance Agency (Anvisa) granted a request by British-Swedish pharmaceutical company AstraZeneca to fast-track the clearance process for its potential Covid-19 vaccine. The decision means that the agency will have access to AstraZeneca’s data as it becomes available, which would save time in the process of getting the vaccine to market — when and if it is proven effective and safe.
The request is a procedure created specifically for emergency situations. However, Anvisa has said it won’t lower its level of scrutiny when analyzing data.
Anvisa says there are currently six potential vaccines being tested in Brazil, notably one produced by Chinese pharmaceutical company Sinovac Biotech, in partnership with São Paulo’s Butantan Institute — which could be available as soon as December, according to São Paulo Governor João Doria.
The agency’s General Manager for Medicines and Biological Products, Gustavo Mendes Lima Santos, said earlier in the week that Anvisa could change its efficacy criteria for the coronavirus vaccine — allowing immunizations with a 50-percent efficacy threshold. The agency’s current standard is 70 percent.
Support this coverage →Speaking before a Senate hearing on Tuesday, Chief of Staff Rui Costa admitted that Brazil…
New job market data from the Brazilian Institute of Geography and Statistics (IBGE) show the…
Brazil officially had 5.83 million domestic workers in 2022 — almost the entire population of…
Brazil’s Ministry of Health this month announced a purchase of 12.5 million doses of Moderna’s…
In a report to the Federal Police, Brazil's Federal Comptroller General’s Office (CGU) denounced irregularities…
Brazil's Justice Ministry reiterated its support for a decision to recreate the Special Commission on…